Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Dyadic International, Inc. DYAI
$1.95
+$0.05 (2.63%)
На 18:01, 12 мая 2023
Ранг: 3
Ключевые показатели
-
Marketcap
54741090.00000000
-
week52high
3.56
-
week52low
1.12
-
Revenue
2930303
-
P/E TTM
-5
-
Beta
0.68304400
-
EPS
-0.31000000
-
Last Dividend
0.00000000
-
Next Earnings Date
10 мая 2023 г. в 20:00
Описание компании
Dyadic International, Inc., a biotechnology platform company, develops, produces, and sells enzymes and other proteins in the United States. The company utilizes its patented and proprietary C1 platform and other technologies to conduct research, development, and commercial activities for the development and manufacturing of human and animal vaccines and drugs, such as virus like particles and antigens, monoclonal antibodies, bi/tri-specific antibodies, fab antibody fragments, Fc-fusion proteins, biosimilars and/or biobetters, and other therapeutic enzymes and proteins. It offers DYAI-100, SARS-CoV-2-RBD antigen vaccine candidate towards a first-in-human Phase 1 clinical trial, is to validate to serve as proof of concept for the development of next generation multivariant COVID-19 vaccine candidates. The company has a research and development agreement with VTT Technical Research Centre of Finland, Ltd.; strategic research services agreement with Biotechnology Developments for Industry in Pharmaceuticals, S.L.U.; and collaboration with Syngene International Limited. Dyadic International, Inc. was founded in 1979 and is headquartered in Jupiter, Florida.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| Dawson James | Neutral | Buy | 18 июл 2022 г. |
| HC Wainwright & Co. | Buy | Buy | 05 апр 2022 г. |
| HC Wainwright & Co. | Buy | 17 дек 2021 г. | |
| HC Wainwright & Co. | Buy | 03 февр 2023 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| Lucy Patrick K. | A | 27174 | 27174 | 03 янв 2023 г. |
| Lucy Patrick K. | A | 35000 | 35000 | 03 янв 2023 г. |
| Buckland Barry | A | 27174 | 27174 | 03 янв 2023 г. |
| Buckland Barry | A | 35000 | 35000 | 03 янв 2023 г. |
| HERBST SETH | A | 27174 | 27174 | 03 янв 2023 г. |
| HERBST SETH | A | 35000 | 35000 | 03 янв 2023 г. |
| Kaye Jack | A | 27174 | 27174 | 03 янв 2023 г. |
| Kaye Jack | A | 52500 | 52500 | 03 янв 2023 г. |
| Tarnok Michael P. | A | 27174 | 27174 | 03 янв 2023 г. |
| Tarnok Michael P. | A | 52500 | 52500 | 03 янв 2023 г. |
Новостная лента
Dyadic International, Inc. (DYAI) Q1 2023 Earnings Call Transcript
Seeking Alpha
10 мая 2023 г. в 22:19
Dyadic International, Inc. (NASDAQ:DYAI ) Q1 2023 Earnings Conference Call May 10, 2023 5:00 PM ET Company Participants Ping Rawson - Chief Financial Officer Mark Emalfarb - President and Chief Executive Officer Joseph Hazelton - Chief Business Officer Conference Call Participants John Vandermosten - Zacks Operator Good evening, and welcome to Dyadic International's First Quarter 2023 Financial Results Conference Call. Currently, all participants are in a listen-only mode.
Dyadic to Report First Quarter 2023 Financial Results on Wednesday, May 10, 2023
GlobeNewsWire
26 апр 2023 г. в 16:30
JUPITER, Fla., April 26, 2023 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial platforms to address the growing demand for global protein bioproduction and unmet clinical needs for effective, affordable and accessible biopharmaceutical products for human and animal health, today announced that it will report its financial results for first quarter 2023 and host a corporate update conference call on Wednesday, May 10, 2023.
Dyadic reports 21.9% revenue rise, $12.7M in cash for full year 2022 as it rapidly advances technology
Proactive Investors
30 мар 2023 г. в 09:51
Dyadic International Inc (NASDAQ:DYAI) posted its financial results for the year ended 2022 with revenue surging 21.9% year-over-year on the back of license agreements as it rapidly advanced its technology. For the year ended December 31, 2022, the Jupiter, Florida-based biotechnology platform company reported research and development (R&D) revenue of $2.93 million, compared to $2.40 million for the year ended December 31, 2021.
Dyadic to Present at World Vaccine Congress Washington 2023
GlobeNewsWire
30 мар 2023 г. в 08:30
JUPITER, Fla., March 30, 2023 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial platforms to address the growing demand for global protein bioproduction and unmet clinical needs for effective, affordable and accessible biopharmaceutical products for human and animal health, today announced that its Chief Executive Officer, Mark Emalfarb will be presenting at the upcoming World Vaccine Congress in Washington, D.C.
Dyadic International, Inc. (DYAI) Q4 2022 Earnings Call Transcript
Seeking Alpha
29 мар 2023 г. в 20:42
Dyadic International, Inc. (NASDAQ:DYAI ) Q4 2022 Results Conference Call March 29, 2023 5:00 PM ET Company Participants Ping Rawson - Chief Financial Officer Mark Emalfarb - President and Chief Executive Officer Joe Hazelton - Chief Business Officer Conference Call Participants John Vandermosten - Zacks Vernon Bernardino - H.C. Wainwright Operator Good evening, and welcome to Dyadic International's Fiscal Year 2022 Financial Results Conference Call.